Key result
Ibutilide exposure, measured by area under the serum concentration-time curve, was not altered in patients with heart failure compared to controls.
Why the study?
Does heart failure due to left ventricular systolic dysfunction alter the pharmacokinetics of ibutilide in adult patients with atrial fibrillation or flutter?
Does heart failure due to left ventricular systolic dysfunction alter the pharmacokinetics of ibutilide in adult patients with atrial fibrillation or flutter?
Ibutilide pharmacokinetics are not altered in patients with HFrEF, indicating that their increased risk of torsade de pointes is likely pharmacodynamic rather than pharmacokinetic.
Answers are grounded in this paper and cite their sources.
Ibutilide exposure appears unaltered in HFrEF; supports pharmacodynamic basis for torsades risk but remains hypothesis-generating.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tisdale et al. (2008) studied Atrial fibrillation or atrial flutter with or without heart failure (n=16). Ibutilide vs. Patients without left ventricular dysfunction was evaluated on Area under the serum concentration-time curve from time zero extrapolated to infinity (microg*hr/L) (p=0.88). Ibutilide exposure, measured by area under the serum concentration-time curve, was not altered in patients with heart failure compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: